guaifenesin has been researched along with rosiglitazone in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Feng, YL; Li, WC; Liu, WJ; Xu, ZB | 1 |
| Gulbins, E | 1 |
| Burcelin, R; Cavin, JB; Ducroc, R; Duszka, K; Kun Tan, C; Mulet, C; Pédron, T; Regnault, B; Saffarian, A; Sansonetti, PJ; Tomas, J; Wahli, W | 1 |
| Cheng, L; Yang, J; Zhao, J; Zhao, R; Zhu, L | 1 |
1 review(s) available for guaifenesin and rosiglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for guaifenesin and rosiglitazone
| Article | Year |
|---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
[Effect of peroxisome proliferators activated receptor gamma and its ligand on airway mucus hypersecretion in rats].
Topics: Animals; Ligands; Male; Mucin 5AC; Mucus; PPAR gamma; Rats; Rats, Sprague-Dawley; Respiratory Mucosa; Rosiglitazone; Thiazolidinediones | 2009 |
Lipids control mucus production in cystic fibrosis.
Topics: Animals; Carbonic Anhydrase II; Carbonic Anhydrase IV; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dinoprostone; Disease Models, Animal; Humans; Hypoglycemic Agents; Mice; Mice, Inbred CFTR; Mucus; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
High-fat diet modifies the PPAR-γ pathway leading to disruption of microbial and physiological ecosystem in murine small intestine.
Topics: Animals; Antimicrobial Cationic Peptides; Cecum; Chlorides; Cystic Fibrosis Transmembrane Conductance Regulator; Diet, High-Fat; Feces; Gastrointestinal Microbiome; Gene Expression Regulation; Intestine, Small; Laser Capture Microdissection; Male; Mice, Inbred C57BL; Mucus; Phenotype; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2016 |
Peroxisome proliferator-activated receptor gamma activation promotes intestinal barrier function by improving mucus and tight junctions in a mouse colitis model.
Topics: Animals; Caco-2 Cells; Colitis; Dextran Sulfate; Disease Models, Animal; HT29 Cells; Humans; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Mucin-2; Mucus; Myosin-Light-Chain Kinase; Permeability; Phosphorylation; PPAR gamma; Rosiglitazone; Signal Transduction; Tight Junctions | 2018 |